Serum Metabolomic Profiling Reveals Potential Mechanisms and Biomarkers of Seladelpar Treatment in Patients With Primary Biliary Cholangitis
Background Seladelpar, a potent and selective peroxisome proliferator‐activated receptor‐δ (PPARδ) agonist, is an approved second‐line therapy for primary biliary cholangitis (PBC) in patients with an inadequate response or intolerance to ursodeoxycholic acid (UDCA). In clinical studies, seladelpar significantly improv...